

Characterization of Long-Term Seizure Freedom in the Ongoing Open-Label Extension of X-TOLE: Potential Implications for Future Clinical Practice

Danielle A. Becker,¹ Jacqueline A. French,² Jenny Qian,³ Joanne M. Wagner,³ Lee Gervitz³

¹The Ohio State University Wexner Medical Center, Columbus, OH, USA; ²New York University Grossman School of Medicine and NYU Langone Health, New York, NY, USA; ³Xenon Pharmaceuticals Inc., Vancouver, BC, Canada


INTRODUCTION

- Seizure freedom is a primary goal of epilepsy management, yet its definition and importance can vary among patients¹
- Patients with epilepsy value different timeframes of seizure freedom, ranging from weeks to years, depending on their personal treatment goals, risks and benefits of antiseizure medications (ASMs), and health-related quality of life factors²⁻⁵
- Understanding patterns of seizure freedom epochs following a breakthrough seizure is clinically relevant for guiding patient expectations and treatment planning
 - As most patients with epilepsy experience a fluctuating clinical course of attaining, losing, and regaining variable periods of seizure control, a single standardized duration of seizure freedom may set unrealistic treatment expectations for seizure management²
 - Provoked (eg, due to missed medication) or unprovoked breakthrough seizures can disrupt periods of seizure control, complicating long-term management⁶
- Long-term open-label extension (OLE) studies investigating ASMs allow continuous observation of seizure patterns, enabling the calculation of various seizure-free epochs to better characterize the dynamic patterns of treatment response
- Azetukalner (AZK) is a novel, potent K_v7 channel opener currently being evaluated in the ongoing 7-year X-TOLE OLE of participants with focal seizures,⁷ for which ≥48-month data in the OLE are being presented⁸
- Using long-term data from the X-TOLE OLE study, we report multiple seizure freedom analyses to better understand how periods of complete seizure control were attained, lost, and regained in a treatment-resistant patient population

METHODS

- The study design for the X-TOLE study (NCT03796962) is shown in **Figure 1**
- The key eligibility criteria and endpoints for X-TOLE and the X-TOLE OLE have been published^{7,9}
- Participants enrolled in the OLE on AZK 20 mg once daily (QD) taken with food. AZK dose adjustments and changes in concomitant ASMs were allowed during the OLE
- Among participants who had completed ≥48 months in the OLE as of the October 6, 2025 data cutoff, seizure freedom was defined as a 100% reduction in seizure frequency from OLE baseline. The following outcomes were assessed:
 - Proportions of participants with ≥12 consecutive months of seizure freedom at the time of last study visit, and subsets of these participants with ≥24 and ≥36 consecutive months of seizure freedom at the time of last study visit
 - Among participants who initially attained an epoch of ≥6 consecutive months of seizure freedom but subsequently experienced a breakthrough seizure, the proportions of participants who later reattained seizure freedom for any consecutive ≥3-, ≥6-, or ≥12-month period

Figure 1. X-TOLE Study Design



RESULTS

- Of the 285 participants who completed the X-TOLE double-blind period (DBP), 275 (96.5%) enrolled in the OLE (**Figure 1**, population characteristics shown in **Table 1**); all 275 participants had an opportunity to complete 48 months of treatment in the OLE
- 131 of the original 275 participants (47.6%) continued in the OLE for ≥48 months (calculated for 28 days per month). As of October 6, 2025, 122 (44.4%) participants continued to participate in the OLE
- At the cutoff date, the OLE has generated >775 patient-years of safety data exposure
- Long-term safety of AZK 20 mg QD in the OLE was comparable with the safety observed in the DBP


Table 1. Demographics and Baseline^a Characteristics of the OLE Population

Characteristics	OLE Population (N=275)
Age at study entry, mean (SD), y	41.1 (13.3)
Sex, n (%)	
Male	137 (49.8)
Female	138 (50.2)
Race, n (%)	
White	250 (90.9)
Black	11 (4.0)
Other	14 (5.1)
Region, n (%)	
North America	109 (39.6)
Europe	166 (60.4)
BMI, mean (SD), kg/m ²	27.0 (5.2)
Age at epilepsy onset, mean (SD), y	18.1 (13.8)
Baseline seizure rate per month, median (IQR)	13.5 (7.9-30.3)
Number of prestudy ASMs tried and discontinued before study entry, mean (SD)	6.5 (3.7)
Background ASM use, n (%)	
1	23 (8.4)
2	108 (39.3)
3	144 (52.4)
CYP3A4 inducer use, n (%)	160 (58.2)

^aDBP baseline. ASM, antiseizure medication; BMI, body mass index; CYP3A4, cytochrome P450 3A4; DBP, double-blind period; IQR, interquartile range; OLE, open-label extension; SD, standard deviation; y, year.

- Seizure freedom analyses for the OLE participants treated for ≥48 months who attained ≥12 consecutive months of seizure freedom at the time of last study visit are shown in **Figure 2**
 - Of the 131 participants in the OLE who had been treated for ≥48 months, 36 (27.5%) attained ≥12 consecutive months of seizure freedom at the time of last study visit
 - Of these 36 participants, 27 (75.0%) and 23 (63.9%) attained ≥24 months and ≥36 consecutive months of seizure freedom at the time of last study visit, respectively


Figure 2. Sustained Seizure Freedom in Participants Treated for ≥48 Months in the OLE at the Time of Last Study Visit: Proportion With ≥12 Consecutive Months of Seizure Freedom, and Among Those Participants, Proportions With ≥24 and ≥36 Consecutive Months of Seizure Freedom



*Data cutoff: October 6, 2025. Monthly seizure rate was calculated for 28 days per month. OLE, open-label extension.

- Seizure freedom pattern analysis for the OLE participants treated for ≥48 months who attained any ≥6 consecutive months of seizure freedom, had a breakthrough seizure, and regained seizure freedom are shown in **Figure 3**
 - Of the 131 OLE participants who had been treated for ≥48 months, 62 (47.3%) attained any ≥6 consecutive months of seizure freedom
 - Among these 62 participants, 29 participants (46.8%) continued to experience seizure freedom (duration mean [SD] of 41.7 [20.6] months), and the other 33 participants (53.2%) subsequently had a breakthrough seizure
 - Of these 33 participants who subsequently had a breakthrough seizure, 27 (81.8%, data not shown), 23 (69.7%), and 19 (57.6%) participants attained a subsequent seizure-free epoch of ≥3, ≥6 or ≥12 consecutive months, respectively, with a mean (SD) duration of regained seizure freedom of 18.9 (16.7) months

Figure 3. Participants Treated for ≥48 Months in the OLE^a Who Attained Any ≥6 Consecutive Months of Seizure Freedom, Had a Subsequent Breakthrough Seizure, and Regained Seizure Freedom



*Data cutoff: October 6, 2025. Monthly seizure rate was calculated for 28 days per month. OLE, open-label extension.

CONCLUSIONS

- This interim analysis of the X-TOLE OLE highlights extended seizure freedom with long-term use of AZK
 - Seizure freedom for ≥12 consecutive months at the time of last study visit was attained by 36 (27.5%) of 131 participants with ≥48 months of treatment in the OLE; 27 (75.0%) and 23 (63.9%) of those 36 participants attained ≥24 and ≥36 consecutive months of seizure freedom, respectively, at the time of the last study visit
- Seizure freedom can be attained, maintained, and, if lost, regained with long-term AZK treatment, even in patients with treatment-resistant disease
 - Of the 33 participants who had a breakthrough seizure after 1 epoch of seizure freedom for any ≥6 consecutive months, 23 (69.7%) and 19 (57.6%) regained ≥6 and ≥12 months of subsequent seizure freedom, respectively
- Collectively, these findings highlight that assessing only a single epoch of seizure freedom may underestimate the full scope of treatment response to AZK over time and offer a deeper understanding of treatment response patterns that may inform future clinical decision-making

References: 1. Halford JJ, Edwards JC. *Acta Neurol Scand.* 2020; 142(2):91-107. 2. Sheikh S, et al. *Epilepsia.* 2019;60(10):2078-2085. 3. Hill CE, et al. *Epilepsy Behav.* 2025;166:110359. 4. Perzynski AT, et al. *Chronic Illn.* 2017;13(3):188-203. 5. Brodie MJ, et al. *Neurology.* 2012;78(20):15481554. 6. Chen H, et al. *Epilepsy Behav.* 2021;124:108330. 7. French JA, et al. *Epilepsia Open.* 2025;10(2):539548. 8. French JA, et al. Presented at: American Epilepsy Society Annual Meeting; December 5-9, 2025; Atlanta, GA. 9. French JA, et al. *JAMA Neurol.* 2023;80(11):11451154.

ACKNOWLEDGMENTS: Medical writing support was provided by Oishika Panda, PhD, CMPP, from Citrus Health Group, Inc. (Chicago, Illinois) and editorial support was provided by Heidi Reinholdt, MS, MA, CMPP, of Helios Global Group; both were funded by Xenon Pharmaceuticals Inc (Vancouver, BC, Canada).

DISCLOSURES: Danielle A. Becker is a consultant/speaker for Neurulis, Inc; SK Life Science; Jazz Pharmaceuticals; LivaNova; Neuropace; and Xenon Pharmaceuticals Inc. (advisory board). Jacqueline A. French has numerous relationships on behalf of the Epilepsy Study Consortium with various commercial and academic entities (consulting, salary support, research support, travel reimbursement, or served on the editorial board), including Xenon Pharmaceuticals Inc. She receives salary support from the Epilepsy Study Consortium and no other income from these relationships. Jenny Qian, Joanne M. Wagner, and Lee Gervitz are employees of and own stock or stock options in Xenon Pharmaceuticals Inc.

FUNDING: This study was funded by Xenon Pharmaceuticals Inc.

These data were previously presented at the American Epilepsy Society Annual Meeting, December 5-9, 2025, Atlanta, GA, USA.

